Company research
Phio Pharmaceuticals Corp.
CIK 1533040Updated Sep 29, 2026
SecurityPHIO · NASDAQ · equity
Historical securities (2)
PHIOW · NASDAQ · warrant · closed Dec 22, 2021RXIIW · NASDAQ · warrant · closed Dec 3, 2024Name history
RXi Pharmaceuticals Corp · through Nov 14, 2018
PHIO price & chart
Loading TradingView…
NASDAQ:PHIO on TradingView ↗About the company
Phio (“Phio”, “we”, “our”, or the “Company”) is a clinical stage biotechnology company whose proprietary INTASYL® small interfering RNA gene silencing technology is designed to make immune cells more effective in killing tumor cells. We are developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body’s ability to fight cancer, without the need for specialized formulations or drug delivery systems. We are committed to discovering and developing innovative cancer treatments for patients by creating new pathways toward a cancer-free future.
In the news
No coverage from other publishers is available.
Recent filings
S-8 filing
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Submission of Matters to a Vote of Security Holders
Items 5.02, 5.07, 9.01
4 filing
4 filing
4 filing
Show 5 more recent filings
4 filing
Other Events
Items 8.01, 9.01
ARS filing
DEFA14A filing
DEF 14A filing
Financials
FY 2025 · USDSource
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 21,487,000Source | 5,738,000Source | 9,364,000Source | 12,814,000Source |
| Property, Plant and Equipment, NetUSD | 11,000Source | 2,000Source | 6,000Source | 183,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 21,031,000Source | 5,382,000Source | — | — |
| Assets, CurrentUSD | 21,476,000Source | 5,736,000Source | 9,322,000Source | 12,446,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 445,000Source | 354,000Source | 832,000Source | 615,000Source |
| Operating Lease, Right-of-Use AssetUSD | — | 0Source | 33,000Source | 161,000Source |
| Other Assets, NoncurrentUSD | — | 0Source | 3,000Source | 24,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 1,340,000Source | 1,015,000Source | 1,634,000Source | 1,974,000Source |
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | 0Source | — | — | — |
| Common Stock, Value, IssuedUSD | 1,000Source | 0Source | 0Source | 0Source |
| Additional Paid in CapitalUSD | 175,200,000Source | 151,079,000Source | 146,936,000Source | 139,218,000Source |
| Retained Earnings (Accumulated Deficit)USD | -155,054,000Source | -146,356,000Source | -139,206,000Source | -128,380,000Source |
| Stockholders' Equity Attributable to ParentUSD | 20,147,000Source | 4,723,000Source | 7,730,000Source | 10,838,000Source |
| Liabilities and EquityUSD | 21,487,000Source | 5,738,000Source | 9,364,000Source | 12,814,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | — | 1,015,000Source | 1,634,000Source | 1,939,000Source |
| Operating Lease, Liability, CurrentUSD | — | 0Source | 35,000Source | 135,000Source |
| Accounts Payable, CurrentUSD | 435,000Source | 253,000Source | 657,000Source | 779,000Source |
| Operating Lease, Liability, NoncurrentUSD | — | 0Source | 0Source | 35,000Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 905,000Source | 762,000Source | 942,000Source | 1,025,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 3,000Source | 2,000Source | 56,000Source | 71,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 481,000Source | 147,000Source | 303,000Source | 414,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts PayableUSD | 183,000Source | -404,000Source | -122,000Source | 496,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -7,979,000Source | -7,112,000Source | -10,749,000Source | -12,129,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -12,000Source | 8,000Source | -5,000Source | -121,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 12,000Source | 1,000Source | 5,000Source | 121,000Source |
| Cash flows from financing activities: | ||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | 30,000Source | 5,000Source | 26,000Source | 28,000Source |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 23,640,000Source | 3,996,000Source | 7,413,000Source | -26,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 15,649,000Source | — | — | — |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | 5,382,000Source | 8,490,000Source | 11,831,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 0Source | 13,000Source | — | — |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 481,000Source | — | — | — |
| DepreciationUSD | — | 2,000Source | 56,000Source | 71,000Source |
| Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber PropertyUSD | — | 6,000Source | — | — |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | 0Source | — | — | — |
| Gain (Loss) on Extinguishment of DebtUSD | — | — | — | 0Source |
| General and Administrative ExpenseUSD | 4,602,000Source | 3,744,000Source | 4,366,000Source | 4,450,000Source |
| Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | -8,698,000Source | -7,150,000Source | -10,826,000Source | -11,480,000Source |
| Nonoperating Income (Expense)USD | — | — | -2,000Source | -18,000Source |
| Operating ExpensesUSD | 9,220,000Source | 7,387,000Source | 10,824,000Source | 11,462,000Source |
| Operating Lease, ExpenseUSD | 31,000Source | — | — | — |
| Other Nonoperating Income (Expense)USD | 2,000Source | — | — | — |
| Proceeds from Issuance of Redeemable Preferred StockUSD | — | — | 0Source | 2,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Operating Income (Loss)USD | -9,220,000Source | -7,387,000Source | -10,824,000Source | -11,462,000Source |
| Other Nonoperating Income (Expense)USD | 2,000Source | — | — | — |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | — | -11,480,000Source |
| Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | -8,698,000Source | -7,150,000Source | -10,826,000Source | -11,480,000Source |
| Earnings Per Share, BasicUSD per share | -1.45Source | -9.08Source | -5.2Source | -10.1Source |
| Earnings Per Share, DilutedUSD per share | — | -9.08Source | -5.2Source | -10.1Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 5,984,017Source | 787,466Source | 2,083,569Source | 1,136,566Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | 787,466Source | 2,083,569Source | 1,136,566Source |
| Additional Financial Items | ||||
| Current Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source | 0Source |
| General and Administrative ExpenseUSD | 4,602,000Source | 3,744,000Source | 4,366,000Source | 4,450,000Source |
| Interest Income (Expense), NetUSD | — | 231,000Source | — | — |
| Investment Income, NetUSD | 520,000Source | — | — | — |
| Nonoperating Income (Expense)USD | — | — | -2,000Source | -18,000Source |
| Operating ExpensesUSD | 9,220,000Source | 7,387,000Source | 10,824,000Source | 11,462,000Source |
| Operating Lease, ExpenseUSD | 31,000Source | — | — | — |
| Other IncomeUSD | — | 6,000Source | — | — |
| Research and Development ExpenseUSD | 4,618,000Source | 3,643,000Source | 6,332,000Source | 7,012,000Source |
Offerings
Registration 333-284381
Filing attachments
phio_ex107.htm · S-1 · 2025-01-21
EX-FILING FEES 4 phio_ex107.htm CALCULATION OF FILING FEE TABLES Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Phio Pharmaceuticals Corp. (Exact Name of Registrant as Specified in Its Charter) Table 1: Newly Registered and Carry Forward Securities Security Security Fee Amount Proposed Maximum Fee Amount Carry …
Read attachment ↗